Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant persister cells (DTPs) which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies. FAK-YAP signaling inhibition combined with the primary targeted therapy suppressed residual drug-tolerant cells and enhanced tumor responses. This study unveils a FAK-YAP signaling module that promotes residual disease in lung cancer and mechanism-based therapeutic strategies to improve tumor response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · cited 1×
“Prominent examples of targeted inhibitors used as fi rst-line treatment in NSCLC are Osi-mertinib and Alectinib for advanced EGFR-mutant or ALK fusion-positive cancers, respectively 2,3 .”
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092 · cited 5×
“Conversely, YAP mayundergo nucleartranslocation in responseto the downregulation of LATS expression or activity through various mechanisms 18,28 .”
InfluentialSelf-citationA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · cited 2×
“1a – c), according to prior literature on the derivation of DTPs under high-dose drug treatment 6,7,9 .”
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527 · cited 1×
“Prominent examples of targeted inhibitors used as fi rst-line treatment in NSCLC are Osi-mertinib and Alectinib for advanced EGFR-mutant or ALK fusion-positive cancers, respectively 2,3 .”
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., et al. (2017) · Nature · doi:10.1038/nature24297 · Cited by 1,799
Mechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667
Organoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556 · cited 1×
“Patient-derived organoid models can recapitulate determinants of treatment response of patient specimens 36,37 , with recent reports focusing on the development of 3D NSCLC organoid cultures 38,39 .”
Self-citationForce triggers YAP nuclear entry by regulating transport across nuclear pores
Elosegui-Artola, A., Andreu, I., Beedle, A. E. M., Lezamiz, A., Uroz, M., Kosmalska, A. J., Oria, R., Kechagia, J. Z., Rico-Lastres, P., Le Roux, A.-L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.008 · Cited by 1,491
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF β-TRCP
Zhao, B., Li, L., Tumaneng, K., Wang, C.-Y., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1843810 · Cited by 1,418 · cited 3×
“Activated LATS, in turn, phosphorylates YAP on serine residues such as Ser127, leading to sequestration in cytoplasm through binding with 14-3-3 protein 18,28 .”
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218 · cited 1×
“Non-genetic mechanisms characterizing the development of drug resistance have been highlighted in recent literature 25,26 .”
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092
Long‐term expanding human airway organoids for disease modeling
Sachs, N., Papaspyropoulos, A., Zomer‐van Ommen, D. D., Heo, I., Böttinger, L., Klay, D., Weeber, F., Huelsz‐Prince, G., Iakobachvili, N., Amatngalim, G. D., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100300 · Cited by 1,082 · cited 1×
“…mixture F12 (DMEM/F-12) GlutaMAX supplement, supplemented with 100 U/mL penicillin/streptomycin, 10 mM HEPES, 25 nM hRspondin, 1x B27, 5mM Nicotinamide, 1.25 mM N-Acetylcysteine, 500 nM A-8301, 500 nM SB202190, 50 µ g/mL Primocin, 100ng/mL hNoggin, 100 ng/ mLhFGF-10,and25ng/mLhFGF-7 67,68 .”
InfluentialHata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985 · cited 5×
“This highlights the concept that differential biological events can characterize each distinct treatment phase, and that DTPs show speci fi cally enriched features therein 6,9 .”
InfluentialOoft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., Schipper, L., Hoes, L., Vis, D. J., van de Haar, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aay2574 · Cited by 813 · cited 1×
“Patient-derived organoid models can recapitulate determinants of treatment response of patient specimens 36,37 , with recent reports focusing on the development of 3D NSCLC organoid cultures 38,39 .”
A gp130–Src–YAP module links inflammation to epithelial regeneration
Taniguchi, K., Wu, L.-W., Grivennikov, S. I., de Jong, P. R., Lian, I., Yu, F.-X., Wang, K., Ho, S. B., Boland, B. S., Chang, J. T., et al. (2015) · Nature · doi:10.1038/nature14228 · Cited by 633
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581 · cited 5×
“This highlights the concept that differential biological events can characterize each distinct treatment phase, and that DTPs show speci fi cally enriched features therein 6,9 .”
InfluentialThe Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
Self-citationKurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.006 · Cited by 475
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Keenan, A. B., Jenkins, S. L., Jagodnik, K. M., Koplev, S., He, E., Torre, D., Wang, Z., Dohlman, A. B., Silverstein, M. C., Lachmann, A., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2017.11.001 · Cited by 423 · cited 2×
“Metadata and identi fi ers associated with each perturbagen were sourced and validated from the iLINCS suite 43 .”
Progenitor identification and SARS-CoV-2 infection in human distal lung organoids
Salahudeen, A. A., Choi, S. S., Rustagi, A., Zhu, J., van Unen, V., de la O, S. M., Flynn, R. A., Margalef-Català, M., Santos, A. J. M., Ju, J., et al. (2020) · Nature · doi:10.1038/s41586-020-3014-1 · Cited by 416
Self-citationA genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway
Mohseni, M., Sun, J., Lau, A., Curtis, S., Goldsmith, J., Fox, V. L., Wei, C., Frazier, M., Samson, O., Wong, K.-K., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2884 · Cited by 294
Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine
Dijkstra, K. K., Monkhorst, K., Schipper, L. J., Hartemink, K. J., Smit, E. F., Kaing, S., de Groot, R., Wolkers, M. C., Clevers, H., Cuppen, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107588 · Cited by 254 · cited 1×
“Patient-derived organoid models can recapitulate determinants of treatment response of patient specimens 36,37 , with recent reports focusing on the development of 3D NSCLC organoid cultures 38,39 .”
Tang, T. T., Konradi, A. W., Feng, Y., Peng, X., Ma, M., Li, J., Yu, F.-X., Guan, K.-L., & Post, L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0717 · Cited by 245
Self-citationDasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
Araujo, J., & Logothetis, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.015 · Cited by 244 · cited 1×
“6e, f), or the multikinase inhibitor dasatinib, which targets SRC downstream of FAK 34 (Supplementary Fig.”
Feng, X., Arang, N., Rigiracciolo, D. C., Lee, J. S., Yeerna, H., Wang, Z., Lubrano, S., Kishore, A., Pachter, J. A., König, G. M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.009 · Cited by 237
Self-citationEmerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189 · cited 1×
“These fi ndings align with previous studies, suggesting that the selection of pre-existing subclones is unlikely to be the only basis for the observed phenotype of drug tolerance 27 .”
Li, P., Silvis, M. R., Honaker, Y., Lien, W.-H., Arron, S. T., & Vasioukhin, V. (2016) · Genes & Development · doi:10.1101/gad.274951.115 · Cited by 180
Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4589 · Cited by 177
Research works printed but not linked: 36
- Bivona, T. G. & Doebele, R. C. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat. Med. 22, 472–478 (2016). · DOI · Paper page
- Maynard, A. et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182, 1232–1251.e22 (2020). · DOI · Paper page
- Shen, S., Vagner, S. & Robert, C. Persistent cancer cells: the deadly survivors. Cell 183, 860–874 (2020). · DOI · Paper page
- Feng, X. et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer cell 25, 831–845 (2014). · DOI · Paper page
- Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246–257 (2013). · DOI · Paper page
- Moroishi, T., Hansen, C. G. & Guan, K.-L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 15, 73–79 (2015). · DOI · Paper page
- Das, A., Fischer, R. S., Pan, D. & Waterman, C. M. YAP nuclear localization in the absence of cell-cell contact is mediated by a filamentous actin-dependent, myosin ii- and phospho-yap-independent pathway during extracellular matrix mechanosensing. J. Biol. Chem. 291, 6096–6110 (2016). · DOI · Paper page
- Miyazawa, A. et al. Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. Biochem Biophys. Res Commun. 495, 2344–2349 (2018). · DOI · Paper page
- Ghasemi, H. et al. Tissue stiffness contributes to YAP activation in bladder cancer patients undergoing transurethral resection. Ann. N. Y Acad. Sci. 1473, 48–61 (2020). · DOI
- Zhao, B., Kim, J., Ye, X., Lai, Z.-C. & Guan, K.-L. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res. 69, 1089–1098 (2009). · DOI · Paper page
- Bell, C. C. & Gilan, O. Principles and mechanisms of non-genetic resistance in cancer. Br. J. Cancer 122, 465–472 (2020). · DOI · Paper page
- Wilson, C. et al. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget 5, 7328–7341 (2014). · DOI · Paper page
- Hsia, D. A. et al. Differential regulation of cell motility and invasion by FAK. J. Cell Biol. 160, 753–767 (2003). · DOI · Paper page
- Lee, B. Y., Timpson, P., Horvath, L. G. & Daly, R. J. FAK signaling in human cancer as a target for therapeutics. Pharmacol. Therapeutics 146, 132–149 (2015). · DOI · Paper page
- Knezevic, N., Tauseef, M., Thennes, T. & Mehta, D. The G protein betagamma subunit mediates reannealing of adherens junctions to reverse endothelial permeability increase by thrombin. J. Exp. Med. 206, 2761–2777 (2009). · doi:10.1084/jem.20090652
- Moroishi, T. et al. The hippo pathway kinases lats1/2 suppress cancer immunity. Cell 167, 1525–1539.e1517 (2016). · DOI · Paper page
- Meraz, I. M. et al. An improved patient-derived xenograft humanized mouse model for evaluation of lung cancer immune responses. Cancer Immunol. Res. 7, 1267–1279 (2019). · DOI · Paper page
- Aissa, A. F. et al. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat. Commun. 12, 1628 (2021). · DOI · Paper page
- Hu, C. et al. Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci. 108, 1347–1356 (2017). · DOI
- Wang, W. et al. Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins. Cell Rep. 13, 524–532 (2015). · DOI · Paper page
- Lange, A. W. et al. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung. J. Mol. Cell Biol. 7, 35–47 (2015). · DOI · Paper page
- LaCanna, R. et al. Yap/Taz regulate alveolar regeneration and resolution of lung inflammation. J. Clin. Invest. 129, 2107–2122 (2019). · DOI · Paper page
- Holden, J. K. et al. Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of hippo pathway signaling. Cell Rep. 31, 107809 (2020). · DOI · Paper page
- Yap, T. A. et al. First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein(YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solidtumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. In AACR Annual Meeting (AACR, Orlando, Florida, 2023). · DOI
- Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D. & Frame, M. C. Targeting FAK in anticancer combination therapies. Nat. Rev. Cancer 21, 313–324 (2021). · DOI · Paper page
- van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218–232 (2020). · DOI · Paper page
- Janse van Rensburg, H. J. & Yang, X. The roles of the Hippo pathway in cancer metastasis. Cell Signal 28, 1761–1772 (2016). · DOI
- Suzuki, K., Bose, P., Leong-Quong, R. Y. Y., Fujita, D. J. & Riabowol, K. REAP: A two minute cell fractionation method. BMC Res. Notes 3, 294 (2010). · DOI · Paper page
- Feng, S. et al. Improved split fluorescent proteins for endogenous protein labeling. Nat. Commun. 8, 370 (2017). · DOI · Paper page
- Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012). · DOI · Paper page
- Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003). · DOI · Paper page
- Guo, Y., Ding, X., Shen, Y., Lyon, G. J. & Wang, K. SeqMule: automated pipeline for analysis of human exome/genome sequencing data. Sci. Rep. 5, 14283 (2015). · DOI
- Hysenaj, L. et al. SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator. bioRxiv https://doi.org/10.1101/2021.06.01.446640 (2021). · DOI
- Haderk, F., Olivas, V. & Bivona, T. G. Immunohistochemistry to study YAP in human tissue samples. Methods Mol. Biol. 1893, 89–95 (2019). · DOI
- Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011). · DOI · Paper page
- Le, B. L. et al. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19. Sci. Rep. 11, 12310 (2021). · DOI
Cited by
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Therapeutic targeting of TEAD transcription factors in cancer
Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147
IMPlications of IMP2 in RNA Biology and Disease
Das, J., Busia-Bourdain, O., Khan, K. M., & Wolfe, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062415 · Cited by 3
Metadata
- Authors
- Haderk, F., Chou, Y.-T., Cech, L., Fernández-Méndez, C., Yu, J., Olivas, V., Meraz, I. M., Barbosa Rabago, D., Kerr, D. L., Gomez, C., Allegakoen, D. V., Guan, J., Shah, K. N., Herrington, K. A., Gbenedio, O. M., Nanjo, S., Majidi, M., Tamaki, W., Pourmoghadam, Y. K., Rotow, J. K., McCoach, C. E., Riess, J. W., Gutkind, J. S., Tang, T. T., Post, L., Huang, B., Santisteban, P., Goodarzi, H., Bandyopadhyay, S., Kuo, C. J., Roose, J. P., Wu, W., Blakely, C. M., Roth, J. A., & Bivona, T. G.
- Venue
- Nature Communications
- Published
- 2024-05-03
- Volume
- 15
- Issue
- 1
- Pages
- 3741-3741
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W4396605932
- Cited by
- 103
- References
- 33
- FWCI
- 18.05
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.